Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
15 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adults (age> 15 years) with ALL standard risk previously untreated. The LAL standard risk is defined by all of the following criteria:
Age less than 30 years
WBC <25x109 / L
Absence of cytogenetic alterations that misbehave forecast or t (9, 22) or demonstration of BCR-ABL rearrangement or alterations in 11q23, or demonstration ALL1-AF4 rearrangement (MLL)
LAL L3 type mature phenotype B (sIg +) or with cytogenetic abnormalities characteristic of Burkitt LAL (t [8, 14], t [2, 8], t [8, 22]). For these patients have the BURKIMAB study.
LAL Ph (BCR-ABL) positive. These patients should be treated with imatinib associated with chemotherapy.
Biphenotypic acute leukemias and bilinear. For these patients treatment is recommended LAM own guidelines.
Acute undifferentiated leukemias. For these patients treatment is recommended LAM own guidelines.
Patients with a history of coronary artery disease, valvular or hypertensive heart disease.
Patients with chronic liver disease.
Patients with chronic respiratory failure.
Renal failure not due to the LAL.
Severe neurological disorders, not due to the LAL.
General State concerned (grades 3 and 4 WHO scale), not attributable to the LAL.